Is fenofibrate safe to use while breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fenofibrate is Contraindicated During Breastfeeding

Fenofibrate should not be used while breastfeeding, and women must discontinue breastfeeding during treatment and for 5 days after the final dose. This is an explicit contraindication based on FDA labeling 1.

FDA Contraindication

The FDA drug label provides clear guidance on this issue:

  • No human data exists on fenofibrate presence in breast milk, effects on breastfed infants, or effects on milk production 1
  • Fenofibrate is present in rat milk, making it likely to be present in human milk 1
  • The primary concern is disruption of infant lipid metabolism, which could have serious consequences for the developing infant 1
  • Women are explicitly instructed not to breastfeed during treatment and for 5 days after the final dose 1

Rationale for Contraindication

The concern about disrupting infant lipid metabolism is particularly significant because:

  • Lipids are critical for infant brain development and growth
  • Fenofibrate's mechanism of action involves altering lipid metabolism through PPARα activation
  • Infants have different metabolic requirements than adults, with higher needs for cholesterol and fatty acids for neurological development
  • The safety profile in infants cannot be extrapolated from adult data

Clinical Approach

If a breastfeeding woman requires lipid management:

  • Discontinue breastfeeding if fenofibrate is medically necessary
  • Consider alternative agents that may be safer during lactation if lipid control is needed
  • Delay fenofibrate therapy until after weaning if the clinical situation allows
  • Wait 5 days after the last dose before resuming breastfeeding if fenofibrate was used

Important Caveat

The animal study showing fenofibrate in rat milk 2 was actually investigating therapeutic effects in offspring, not safety concerns, but it confirms drug transfer into milk. The absence of human data combined with the theoretical risk to infant lipid metabolism justifies the conservative FDA contraindication.

Human Guidelines 3, 4 focus on cardiovascular safety and drug interactions but do not address lactation, making the FDA drug label 1 the authoritative source for this specific question.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.